Company intelligence / Profile preview

GOLO

Newark, Delaware, United Statesgolo.com ↗

Ownership: Private
Development stage: Commercial

Overview

GOLO offers a commercial weight management program combining dietary modification, lifestyle coaching, and its proprietary Release nutraceutical supplement. Multiple pilot studies—including an open-label study in type 2 diabetes—have shown improvements in weight loss, glycemic control (A1C), insulin resistance markers, cholesterol levels, and inflammation. However, most studies are preliminary or open-label; the program is not FDA-evaluated as a drug or device.

Therapeutic areas: Endocrinology
Modalities: Non-pharmacological therapyNutraceutical
Industry: Food & Nutrition

Drug pipeline

4 assets

Release

Commercial

Indications: weight management, metabolic health

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on GOLO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GOLO.

Explore the full profile